Michael Dosch pSC autoimmunity in human T1D. a, Proliferative T-cell responses to GFAP (green) and S100ß (yellow) in peripheral blood mononuclear cells from newly diabetic children, ICA ...

For type 1 diabetes, immunotherapy approaches show promise for delaying beta cell destruction when administered early in diagnosis. Researchers are also exploring beta cell transplantation ...

In Type 1 diabetes, the immune system mistakes the body’s healthy cells for foreign ones and tries to fight them. In this case, the immune system attacks and destroys the insulin-producing beta ...

according to a doctor Type 1 diabetes is an autoimmune disease where beta cells, a hormone located in the pancreas that ...

The study explores whether Prolia/Xgeva (denosumab), a widely used therapy for osteoporosis and bone tumors, can regenerate ...

CellTrans has claimed the first FDA approval for a cell therapy used to treat type 1 diabetes, consisting of insulin-producing islet beta cells taken from deceased donors. The Chicago-based ...

Type 1 diabetes is an immune-mediated disease ... T cells in a sea of nonspecific bystanders can drive complete beta-cell destruction 15, the question of whether there is a particular TCR that ...

While its exact cause is not clear, Type 1 diabetes is believed to be impacted by an autoimmune reaction, states the CDC. This leads to the destruction of beta cells. If you have Type 1 diabetes ...

The family of medications called GLP-1 receptor agonists includes drugs like Wegovy, Zepbound, Ozempic, Mounjaro and Victoza.

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial. The ...